Non-Exclusive $1.373 Billion Deal Signed in 2019
SC Formulation Conversion Platform Expands to Eight Global Big Pharma Companies

On June 18, Alteogen revealed that its first licensing partner for the subcutaneous (SC) formulation conversion using ALT-B4, based on the Hybrozyme® platform signed in 2019, is Sanofi.


Alteogen Reveals Sanofi as First ALT-B4 License Partner View original image

In November 2019, Alteogen entered into a non-exclusive license agreement for ALT-B4 with one of the world’s top 10 pharmaceutical companies, announcing a total deal value of 1.373 billion dollars. At the time, the partner’s name was kept confidential in accordance with the terms of the agreement.


Alteogen’s Hybrozyme technology, starting with the agreement with Sanofi, has since led to licensing deals with eight global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo, Biogen, Sandoz, and Intas.



Tae Yeon Jeon, CEO of Alteogen, said, “By disclosing the partner, we are able to reaffirm the competitiveness of the ALT-B4 platform technology,” adding, “We expect that news of clinical development progress will further increase interest in ALT-B4.” He continued, “ALT-B4, which is being applied to various modalities such as monoclonal antibodies, bispecific antibodies, and ADCs, is providing fast and convenient administration options in multiple therapeutic areas, including oncology and autoimmune diseases, making its necessity increasingly evident.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing